StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$127.16+2.49 (+2.00%)

Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –

Protagonist Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Protagonist Therapeutics's pe ratio was 130.9× on Nov 11, 2026, against 63.3× a year earlier. Over the last 2 years it ranged from 8.9× to 145.2×, with a median of 63.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026130.9×−9.9
2025Dec 31, 2025140.9×+126.4
2024Dec 31, 202414.5×–

More Protagonist Therapeutics figures

See a number that looks wrong?